CompanyJANXNasdaqSan Diego, CA

Janux Therapeutics

Janux develops immunotherapies using TRACTr, TRACIr, and ARM platforms.

SEC EDGAR ClinicalTrials.gov januxrx.com

424B3Sep 10Latest SEC filing

Sep 10Latest story

September 2026

Janux Therapeutics opens Phase 1 combo trial of JANX013 and JANX007 in mCRPC

Sep 10Trial updateJanux Therapeutics JANX007

August 2026

Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on track

Aug 6Quarterly updateJanux Therapeutics JANX007